Tavaborole

CHEMBL443052 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
151.9 g/mol
LogP
Phase
4

Tavaborole is a topical oxaborole antifungal agent that inhibits fungal cytoplasmic leucyl-transfer RNA synthetase (LeuRS), a novel mechanism distinct from azoles and allylamines. It is approved for the treatment of onychomycosis (fungal nail infection) caused by Trichophyton rubrum and T. mentagrophytes. Its low molecular weight allows effective nail plate penetration, overcoming a major limitation of topical antifungal therapy.

Peso molecular

151,9300 g/mol

TPSA

29,50 Ų

Mecanismo de acción

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

OB1OCc2cc(F)ccc21

InChI

InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2

Molecular Formula

C7H6BFO2

HBD / HBA

1 / 3

Enlaces Rotables

0

Átomos Pesados

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Tavaborole is a topical oxaborole antifungal agent that inhibits fungal cytoplasmic leucyl-transfer RNA synthetase (LeuRS), a novel mechanism distinct from azoles and allylamines. It is approved for the treatment of onychomycosis (fungal nail infection) caused by Trichophyton rubrum and T. mentagrophytes. Its low molecular weight allows effective nail plate penetration, overcoming a major limitation of topical antifungal therapy.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Tavaborole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL443052. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11499245. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.